Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial
Transfusion · 2026-01 · 66 (1) · 72-83
DOI: 10.1111/trf.70009 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Transfusion, online erschienen am 29.11.2025. Verfasst von Ian J Welsby und 11 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Hemoglobins, Cardiac Surgical Procedures, Glutathione. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Background
The ReCePI randomized, controlled trial compared amustaline/glutathione pathogen‐reduced (PR) and conventional red blood cell (RBC) transfusions in cardiac surgery. Study design and methods We performed a post‐hoc analysis of hemoglobin (Hb) utilization and safety outcomes. Hb content of study RBCs was measured at manufacture. Subject Hb levels, estimated blood loss and blood product use were recorded during and for 7 days post‐surgery. Acute kidney injury (AKI) incidence was graded over 7 days, and adverse events were assessed for 28 days.
Results
PR‐RBCs contained 5.2% less Hb (mean [SD] Test 58.1 [6.5] g; Control 61.5 [6.8] g Hb, p < .001) due to manufacturing volume losses. Four hundred fifty‐six PR‐ and 524 conventional RBCs were transfused to 159 Test and 162 Control subjects, respectively. Mean subject baseline and post‐surgery Hb levels, and blood loss were not different between groups. Test subjects tended to require fewer total RBCs (3.5 [2.7] Test vs. 4.0 [3.5] Control, p = .08) resulting in 17.6% significantly less mean total Hb transfused (Test 203.2 g; Control 246.8 g Hb, p = .01). The proportions of subjects transfused with, and the number of platelet and cryoprecipitate units transfused were not different. Test subjects received less plasma (2.3 [1.8] units Test vs. 3.5 [3.8] Control, p = .03). Overall incidence of adverse events and AKI were not clinically different. Imbalances in AKI severity (Grade III Test 15/159 [9.4%]; Control 7/162 [4.3%], p = .07) may suggest under‐transfusion in the highest‐risk Test subjects.
Discussion
Test patients required less transfused Hb than control subjects to maintain equivalent daily hemoglobin levels following similar blood loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University Medical Center, Durham, North Carolina, USA.
- Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA.
- Yale University School of Medicine, New Haven, Connecticut, USA.
- University of Virginia Health System, Charlottesville, Virginia, USA.
- Cerus Corporation, Concord, California, USA.
ORCID-Profile: James D Gorham
Förderung
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Welsby, I. J., Sekela, M. E., Snyder, E. L., Gorham, J. D., McNeil, J. S., Liu, K., Bentow, S., Gniadek, T., Corash, L., Mufti, N., Benjamin, R. J., & ReCePI Study Group (2026). Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial. Transfusion, 66(1), 72-83. https://doi.org/10.1111/trf.70009
Vancouver
Welsby IJ, Sekela ME, Snyder EL, Gorham JD, McNeil JS, Liu K, et al. Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial. Transfusion. 2026;66(1):72-83. doi:10.1111/trf.70009
BibTeX
@article{Welsby2026,
author = {Welsby, Ian J and Sekela, Michael E and Snyder, Edward L and Gorham, James D and McNeil, John S and Liu, Kathy and Bentow, Stanley and Gniadek, Thomas and Corash, Laurence and Mufti, Nina and Benjamin, Richard J and ReCePI Study Group, ReCePI Study Group},
title = {Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {1},
pages = {72--83},
doi = {10.1111/trf.70009}
}
EUVIMED